Refusal of treatment among HER2-positive breast cancer patients in China: a retrospective analysis
BackgroundThere is a need to update the understanding of treatment refusal among cancer patients in China, taking into account recent developments. This study investigated how public insurance coverage of the first breast cancer targeted therapy contributed to the changes in treatment refusal among...
Saved in:
Main Authors: | Xin Wang (Author), Zhiwei Lian (Author), Qiyou Wu (Author), Fan Wu (Author), Gong Zhang (Author), Jian Liu (Author), Chuanben Chen (Author), Jing Sun (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Factors associated with the uptake of biosimilars for breast cancer treatment from the perspectives of physicians and patients-Evidence from China
by: Qiyou Wu, et al.
Published: (2023) -
Uptake of biosimilars in China: a retrospective analysis of the case of trastuzumab from 2018 to 2023
by: Qiyou Wu, et al.
Published: (2024) -
The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
by: Zihong Wu, et al.
Published: (2023) -
Survival outcomes of beta-blocker usage in HER2-positive advanced breast cancer patients: a retrospective cohort study
by: Hui-Hsia Hsieh, et al.
Published: (2023) -
Educational Case: HER-2 Positive Breast Cancer
by: Julia Jennings MD, et al.
Published: (2021)